- Home
- KOD vs MGEE Comparison
KOD vs MGEE Comparison
Compare KOD & MGEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KOD | MGEE |
|---|---|---|
| Founded | 2009 | 1855 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Electric Utilities: Central |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.9B |
| IPO Year | 2018 | 2001 |
Fundamental Metrics
Financial Performance| Metric | KOD | MGEE |
|---|---|---|
| Price | $36.16 | $74.89 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 7 | 2 |
| Target Price | $35.43 | ★ $80.50 |
| AVG Volume (30 Days) | ★ 548.2K | 274.1K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 2.41% |
| EPS Growth | N/A | ★ 11.71 |
| EPS | N/A | ★ 1.32 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $4.02 |
| Revenue Next Year | N/A | $2.77 |
| P/E Ratio | ★ N/A | $57.16 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.33 | $72.17 |
| 52 Week High | $47.84 | $91.46 |
Technical Indicators
Market Signals| Indicator | KOD | MGEE |
|---|---|---|
| Relative Strength Index (RSI) | 38.60 | 40.00 |
| Support Level | $21.82 | $72.59 |
| Resistance Level | $46.72 | $82.48 |
| Average True Range (ATR) | 3.01 | 1.77 |
| MACD | -1.28 | -0.51 |
| Stochastic Oscillator | 0.19 | 22.41 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
About MGEE MGE Energy Inc
MGE Energy provides electric service to 170,000 customers and natural gas service to 180,000 customers in Madison, Wisconsin, and surrounding areas. Nearly 90% of customers are residential. The company also owns a 3.6% stake in American Transmission Co. MGE owns interests in two coal power plants that earn guaranteed fixed rates of return, contributing about 20% of earnings.